Skip to main navigation Skip to search Skip to main content

An Unusual Case of Ipilimumab/Nivolumab Induced Fulminant Diabetic Ketoacidosis (DKA) in a Non Diabetic Patient - a Case Report

  • Randa Abdelmasih
  • , Ramy Abdelmaseih
  • , Jay D Patel
  • , Elio P Monsour
  • , Khalid Abusaada
  • HCA Healthcare

Research output: Contribution to journal › Article › peer-review

Original languageAmerican English
JournalEndocrinology
StatePublished - May 8 2020

Keywords

  • immune checkpoint inhibitors
  • drug-related side effects and adverse reactions

Disciplines

  • Endocrine System Diseases
  • Endocrinology, Diabetes, and Metabolism

Cite this